US 2023/0399410 A1 · COMPOSITIONS AND METHODS FOR TREATING POLYMYALGIA RHEUMATICA BY ADMINISTERING AN IL-6R ANTAGONIST

Compositions and methods for treating polymyalgia rheumatica by administering an il-6r antagonist

AssigneesSanofi Biotechnology, Regeneron Pharmaceuticals, Inc.

InventorsJennifer SLOANE LAZAR, Yong LIN, Wanling WONG, Ying LIU, Frédéric MARRACHE, Kerri FORD, Stefano FIORE, Lita ARAUJO, Danielle ISAMAN, Jeffrey CURTIS, Chad NIVENS, Bola AKINLADE, Angeliki GIANNELOU

Life of this patent

Estimating the term…

Abstract

The present disclosure relates to the use of an anti-IL6 receptor antibody, or an antigen-binding fragment thereof, for treating polymyalgia rheumatica (PMR).

Claims51

Dependent claims

A method for treating polymyalgia rheumatica (PMR) in a subject in need thereof, comprising administering an effective amount of an antibody or antigen-binding fragment thereof that specifically binds IL-6 receptor.

A method of reducing or eliminating the dependence of a subject with polymyalgia rheumatica (PMR) on a background therapy comprising corticosteroids for the treatment of PMR comprising:

(a) selecting a subject who has PMR that is partially controlled or uncontrolled with a background therapy comprising corticosteroids;
(b) administering to the patient a defined dose of a therapeutically effective amount of an antibody or antigen-binding fragment thereof that specifically binds IL-6 receptor at a defined frequency for an initial treatment period while maintaining the subject's background PMR therapy for the initial treatment period;
and
(c) gradually reducing or eliminating the dosage of corticosteroids administered to the subject over the course of a subsequent treatment period while continuing to administer the antibody or antigen-binding fragment thereof to the subject at the defined frequency and dose used during the initial treatment period.

1 more element

Dependencies are inferred from the claim text.